Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ST-0529 in moderately to severely active ulcerative colitis
2018-003349-41Phase 2Terminated
- Sponsor
- Sublimity Therapeutics
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing ST-0529 with Placebo (2 arms). Primary endpoint: Clinical remission at Week 12. Started Dec 2018; status: terminated.
02
Drugs
STI-0529
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2018-003349-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003349-41.